BIT Capital’s Dianthus Therapeutics DNTH Stock Holding History

BIT Capital’s Portfolio DNTH Stock Details DNTH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.17M	Hold	12,000	–	–	0.03%	74
2026 Q1	$1.01M	Sell	12,000 -3,000	-20%	-$174K	0.05%	61
2025 Q4	$618K	Buy	+15,000	New	+$582K	0.02%	86
2022 Q4	–	Sell	-10,733	Closed	-$230K	–	150
2022 Q3	$230K	Buy	10,733 +5,952	+124%	+$163K	0.04%	119
2022 Q2	$95.6K	Buy	4,781 +2,187	+84%	+$54.1K	0.01%	99
2022 Q1	$140K	Buy	+2,594	New	+$142K	0.01%	98

Other funds holding DNTH

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

APM

Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return

OCA

Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return

BIT Capital's DNTH Position: Q2 2026 in Review

BIT Capital held its Dianthus Therapeutics (DNTH) position steady in Q2 2026 at 12,000 shares worth $1.17M. The position accounts for 0.03% of the portfolio, ranked #74.

BIT Capital first reported a position in DNTH in Q1 2022 and has held it in 6 quarters since. 269 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

BIT Capital held 12,000 shares of Dianthus Therapeutics worth $1.17M as of Q2 2026.
BIT Capital left its Dianthus Therapeutics share count unchanged in Q2 2026.
Dianthus Therapeutics made up 0.03% of BIT Capital's portfolio in Q2 2026, its #74 holding.
BIT Capital first reported a position in Dianthus Therapeutics in Q1 2022 and has held it in 6 quarters since.
269 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on BIT Capital's 13F filing for Q2 2026, filed 12 Aug 2026.